Skip to main content
. 2023 May 5;12(1):24. doi: 10.1038/s41389-023-00472-4

Fig. 7. Vortioxetine hydrobromide inhibited the growth of patient-derived xenograft (PDX) tumor in vivo.

Fig. 7

A Patient information of different PDX cases: type, gender, age, clinical phases and pathological grade. B HSG 288 and LSG85 SCID mice received 1.5 mg/kg and 12 mg/kg vortioxetine hydrobromide once a day. Photographs of tumors for LSG85 (n = 8) and HSG 288 (n = 9). C Tumor volumes were measured every 3 days. Tumor growth curve after vortioxetine hydrobromide treated for LSG85 (n = 8) and HSG 288 (n = 9). D Tumor weights were measured every 2 days. E The tumor growth inhibition of vortioxetine hydrobromide. Statistical analysis of Ki67 and p-STAT3 Y705 protein levels in LSG85 (F) and HSG288 (G). Vortioxetine hydrobromide-treated groups were normalized to the vehicle group. H The protein levels of p-STAT3 Y705, STAT3, Bcl2, Mcl1 and c-Myc of tumor tissues were detected by Western blotting. Mean ± S.D. (n = 3) (*p < 0.05, **p < 0.01, ***p < 0.001).